Today: 20 March 2026
Subscribe
Browse Category

NASDAQ:NXT 12 November 2025 - 12 January 2026

Nextpower (NXT) stock jumps on Saudi joint venture launch and 12‑GW factory plan

Nextpower (NXT) stock jumps on Saudi joint venture launch and 12‑GW factory plan

Nextpower shares rose about 9% Monday after the company confirmed its Saudi joint venture and detailed plans for a Jeddah manufacturing facility targeting 12 GW annual solar tracker capacity by Q2 2026. The stock reached $99.70 before settling at $99.62. Partners plan to invest $88 million over two years. Traders await updates on orders and spending at the Jan. 27 earnings call.
12 January 2026
··
Nextpower (NXT) stock slides as solar shares wobble; $90 level and earnings in focus

Nextpower (NXT) stock slides as solar shares wobble; $90 level and earnings in focus

Nextpower shares dropped 3.9% to $89.18 Monday, erasing an early surge and closing $3.60 below Friday’s finish. The move returned the stock to a key technical support zone after last year’s solar rally. Traders are watching for the company’s fiscal Q3 earnings, expected between Jan. 27 and Feb. 2. Broader solar stocks were mixed as investors awaited U.S. economic data for rate clues.
5 January 2026
······
Nextracker Rebrands as Nextpower: NXT Stock Slips as Company Unveils Power‑Conversion Push and Long‑Term Targets (Nov. 12, 2025)

Nextracker Rebrands as Nextpower: NXT Stock Slips as Company Unveils Power‑Conversion Push and Long‑Term Targets (Nov. 12, 2025)

Nextracker Inc. has changed its name to Nextpower Inc. and unveiled a new power-conversion systems line, set to ship in 2026. The company reaffirmed FY26 guidance, introduced FY27 outlook, and targets $4.8–$5.6 billion revenue by FY30, with about one-third from non-tracker products. Shares fell 9.4% to $95.88 after the announcement. The Nasdaq ticker remains NXT.
12 November 2025
··

Stock Market Today

  • Regeneus Ltd (RGS.AX) Jumps 33% on Heavy Volume, Signals Short-Term Upside
    March 19, 2026, 10:42 PM EDT. Regeneus Ltd (RGS.AX) surged 33.33% to A$0.012 on March 20, 2026, driven by unusually heavy volume of 4.28 million shares, nearly seven times the average. The stock broke above its 50-day and 200-day moving averages, indicating increased short-term trader interest in this clinical-stage biotech focused on osteoarthritis and wound healing. Despite negative earnings per share and liquidity constraints, the price action reflects momentum trading in a volatile sector. Traders should watch intraday support at A$0.010 and resistance near the year high of A$0.020. With a Meyka AI rating of 64.90 (Grade B), the stock is rated HOLD amid high volatility and thin order books typical of small-cap biotechs on the Australian Securities Exchange (ASX).
Go toTop